Close Menu


Earlier this year, Santaris sued Mirrx for allegedly using illegally obtained trade secrets to file European patent applications on a miRNA-inhibiting technology with therapeutic applications. The legal battle has raised questions about Santaris' HCV drug miravirsen.

Marina Biotech, formerly MDRNA, said that it changed its name to reflect "the marine nature of our two locations — Puget Sound and Boston Harbor — while preserving our Nasdaq ticker, MRNA."

Caliper has denied that it is infringing a Carestream patent and has asked that certain patent claims be declared invalid or unenforceable.

PGxHealth has charged Toronto Research Chemicals and Santa Cruz Biotechnology for infringement because they both market the compound apadenoson, the primary ingredient of Stedivaze, a coronary vasodilator that PGxHealth is developing for myocardial perfusion imaging.

The suit stems from the firms' 1991 asset purchase agreement and a subsequent settlement agreement between Applied Biosystems and Molecular Diagnostic Laboratories. AB claims Roche owes it money associated with that settlement.

The dispute stems from a licensing agreement in 2005 covering reagent patents held by Abaxis. Cepheid filed a countersuit yesterday, claiming it has not breached the license and asking the court to declare Abaxis' patents invalid.

Siemens is asking a federal court to grant it rights to a patent covering nucleic acid amplification technology instead of Enzo.

Carestream has alleged that Caliper's IVIS Lumina XR Imaging System infringes a recently issued patent.

The decision means that Taconic has no right to create and sell transgenic animal models, and "confirms that the products sold by Taconic, namely transgenic animals constructed using the teaching of the patents, could not and still cannot be bred by a third party," Cellectis said.

The lawsuit claims that Invitrogen and CellzDirect are infringing a Celsis patent that relates to processes and methods for producing cryopreserved hepatocytes.


Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.